Department:	Pharmacy Management	**Original Approval:**	04/09/2025
Policy No:	PM605	**Last Approval:**	04/09/2025
Policy Title:	ADAMTS13, Recombinant-krhn (Adzynma) Clinical Coverage Criteria		
Approved By:	UM Criteria Subcommittee		
Applicable Line(s) of Business:	☐ **Washington Apple Health (Medicaid)** ☐ **Behavioral Health Services Only** ☐ **Apple Health Expansion** ☒ **Medicare Advantage/Special Needs Plan** ☒ **Medicare Advantage Only** ☒ **Cascade Select**		

Required Clinical Documentation for Review

Documentation required to determine medical necessity for Adzynma (ADAMTS13, Recombinant-krhn):

1. History and/or physical examination notes and relevant specialty consultation notes that address the problem and need for the service
2. Diagnosis
3. Labs/Diagnostics
4. Dosing and duration requested
5. Initial/Extended approval
6. Medical records from the last 6 months showing the patient's problems, history, prior treatments, response to treatment, imaging and laboratory studies, details of the skilled needs, details of any specific needs related to risk/trauma/cultural etc., assessment and plan
7. Prescribed by or in consultation with a specialist, when indicated.

Background

Adzynma (ADAMTS13, Recombinant-krhn) is an intravenously human-recombinant ADAMTS13 (A disintegrin and metalloproteinase with thrombospondin motifs 13) indicated for prophylactic therapy or on demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).[1] ADAMTS13 is a plasma zinc metalloprotease that cleaves large and ultra-large von Willebrand factor (VWF) multimers into smaller units, reducing the platelet-aggregating effects of VWF.

Congenital thrombotic thrombocytopenic purpura (cTTP) is most often detected in childhood or during pregnancy.[2] cTTP clinically presents as macroangiopathic hemolytic anemia (MAHA) with severe thrombocytopenia and variable organ ischemia (most commonly neurologic, cardiac, or renal), resulting from platelet adhesion and aggregation in an environment of VMF dysregulation. Diagnosis is confirmed with molecular genetic testing of the ADAMTS13 gene or by ADAMTS13 activity testing showing < 10% of normal activity.

Guidelines

The 2020 International Society on Thrombosis and Haemostasis *Guidelines for treatment of thrombotic thrombocytopenic purpura* do not endorse use of plasma infusion over a watch and wait strategy in patients with cTTP in remission as the determination of treatment strategy is dependent on clinical circumstance of the patient given the requirement of substantial infrastructure resources, large volume of plasma, and burden of treatment on the patient.[3] In acute episodes, therapeutic plasma exchange (TPE) with fresh frozen plasma (FFP) replacement is first-line therapy in TTP.[2] Currently, guidelines do not include recommendations for recombinant ADAMTS13.

Clinical Trials

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) is currently recruiting and in progress with estimated completion by 03/16/2027.[4] Enrolled patients will be randomized to receive recombinant ADAMTS13 for prophylactic treatment on a weekly/biweekly schedule or for an "on-demand" treatment schedule for acute TTP events.

In a Phase 3, open-label, crossover trial, 48 patients were randomized to receive prophylaxis with either recombinant ADAMTS13 or standard therapy (plasma-derived products).[5] Treatment with weekly or biweekly prophylaxis with recombinant ADAMTS13 resulted in 100% ADAMTS13 activity versus 19% ADAMTS13 activity in patients receiving standard therapy. Adverse events occurred in 71% of patients receiving recombinant ADAMTS13 versus 84% of patients receiving standard therapy.

Definitions

N/A

Indications/Criteria

Medicaid Members	***Excluded benefit. Authorization and billing required directly through WA Apple Health Fee for Service only. Call 800-562-3022.***

Individual & Family (Cascade Select) Members	***Continue to criteria for approval below.***
Medicare Members	***Continue to criteria for approval below.***

FDA-Approved Indications

1. **Congenital Thrombotic Thrombocytopenic Purpura (cTTP) – Prophylactic and Acute.**
   Initial Authorization. Approve for the duration noted if the patient meets the following criteria (A, B, and C):
   - **A)** The patient is ≥ 2 years of age; AND
   - **B)** Diagnosis of cTTP is confirmed by one of the following methods (i or ii):
     - **i.** Molecular genetic testing demonstrating mutation of the ADAMTS13 gene; OR
     - **ii.** ADAMTS13 activity testing demonstrating < 10% of normal ADAMTS13 activity; AND
   - **C)** The medication is prescribed by or in consultation with a hematologist, oncologist, or genetic medicine physician.

   Reauthorization. The patient has previously received Adzynma for management of cTTP. Approve for the duration noted if the patient meets the following criteria (A and B):
   - **A)** The patient continues to meet initial approval criteria; AND
   - **B)** The patient has had a positive clinical response (e.g., as evidenced by increased platelet counts, fewer TTP exacerbations, reduced serum lactate dehydrogenase levels) compared to baseline as determined by the prescriber.

   Dosing. Approve for ONE of the following regimens (A, B or C):
   - **A)** **Prophylactic Therapy – Initial Authorization.** Approve for 6 months with treatment plan of Adzynma 40 IU/kg, administered not more frequently than once every week; OR
   - **B)** **Prophylactic Therapy – Reauthorization.** Approve for 1 year with treatment plan of Adzynma 40 IU/kg, administered not more frequently than once every week; OR
   - **C)** **On-Demand Enzyme Replacement Therapy.** Approve for 1 month with treatment plan of Adzynma 40 IU/kg on day 1, 20 IU/kg on day 2, and 15 IU/kg daily on day 3 and beyond (until two days after acute event is resolved).

Special Considerations

None

Limitations/Exclusions

Please see link to member coverage documents below:

Line of Business	Link to Member Coverage Documents
Medicare Advantage Plans (Including D-SNP)	https://medicare.chpw.org/ Select the appropriate plan from the "Plans" drop down on the top navigation bar.
Apple Health	https://www.chpw.org/for-members/benefits-and-coverage-imc/
Cascade Select	https://chnwhealthinsurance.chpw.org/member-center/plan-benefits/

List of Appendices

None

Citations & References

CFR	42 CFR § 438.210	
WAC	WAC 284-43-2050	
RCW		
LOB & Contract Citation	☐ **WAHIMC**	
	☐ **BHSO**	
	☐ **Wraparound**	
	☐ **SMAC**	
	☐ **HH**	
	☐ **AHE**	
	☒ **MA/DSNP**	P&P supports all LOB requirements
	☒ **CS**	P&P supports all LOB requirements
Other Requirements		
NCQA Elements		
References	1. ADZYNMA (ADAMTS13, recombinant-krhn) lyophilized powder for Injection, for intravenous use [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; 2023. 2. Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536. 3. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic	

thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2496-2502.
4. ClinicalTrials.gov A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Available at: https://clinicaltrials.gov/ct2/show/NCT04683003. Last accessed March 2025
5. Scully M, Antun A, Cataland SR, Coppo P, Dossier C, Biebuyck N, Hassenpflug WA, Kentouche K, Knöbl P, Kremer Hovinga JA, López-Fernández MF, Matsumoto M, Ortel TL, Windyga J, Bhattacharya I, Cronin M, Li H, Mellgård B, Patel M, Patwari P, Xiao S, Zhang P, Wang LT; cTTP Phase 3 Study Investigators. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2024 May 2;390(17):1584-1596.

Revision History

Revision Date	Revision Description	Revision Made By
04/08/2025	New policy	Michael Tom, PharmD; Alan Gabot, PharmD
04/09/2025	Approval	UM Criteria Subcommittee